Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-regimen study of HB0017 injection in moderate-to-severe plaque psoriasis
CTR20243283Phase 2Active
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HB0017 in plaque psoriasis, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Sep 2024; status: active.
02
Drugs
HB0017
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20243283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243283.